AlzeCure Pharma announces CEO change ahead of next development phase

LLY•2026-11-11

AlzeCure Pharma announced a CEO change as it prepares to advance licensing collaborations with Eli Lilly and QuantumCell and develop its Painless pain platform.

1. Next development phase

AlzeCure Pharma announced a CEO change ahead of a development phase focused on advancing licensing collaborations with Eli Lilly and QuantumCell, alongside development of its Painless pain platform.

Sources

AlzeCure Pharma announces CEO change ahead of next development phase

Publicnow

AlzeCure Pharma announces CEO change ahead of next development phase

1. Next development phase

Related News

Mentari Therapeutics: TD Cowen initiates coverage with buy rating

Ambiq Micro, Inc.: Jefferies cuts target price to $70 from $90

KB Securities faces KRW 332.18 billion fine over alleged government bond bid rigging

Sources

AlzeCure Pharma announces CEO change ahead of next development phase

Delivery Hero lowers bond conversion price after Uber takeover offer acceptance trigger

Himalaya Shipping preliminary Q3 total time charter revenues $62.2 million